RT Journal Article
SR Electronic
T1 Estimation of global case fatality rate of coronavirus disease 2019 (COVID-19) using meta-analyses: Comparison between calendar date and days since the outbreak of the first confirmed case
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.11.20128959
DO 10.1101/2020.06.11.20128959
A1 Ghayda, Ramy Abou
A1 Lee, Keum Hwa
A1 Han, Young Joo
A1 Ryu, Seohyun
A1 Hong, Sung Hwi
A1 Yoon, Sojung
A1 Jeong, Gwang Hun
A1 Lee, Jinhee
A1 Lee, Jun Young
A1 Yang, Jae Won
A1 Effenberger, Maria
A1 Eisenhut, Michael
A1 Kronbichler, Andreas
A1 Solmi, Marco
A1 Li, Han
A1 Jacob, Louis
A1 Koyanagi, Ai
A1 Radua, Joaquim
A1 Shin, Jae Il
A1 Smith, Lee
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128959.abstract
AB Since the outbreak of the coronavirus disease 2019 (COVID-19) in December of 2019 in China, the estimation of the pandemic’s case fatality rate (CFR) has been the focus and interest of many stakeholders. In this manuscript, we prove that the method of using the cumulative CFR is static and does not reflect the trend according to the daily change per unit of time. A proportion meta-analysis was carried out on CFR in every country reporting COVID-19 cases. Based on the results, we performed a meta-analysis for global COVID-19 CFR. Each analysis was performed on two different calculations of CFR: according to calendar date and according to days since the outbreak of the first confirmed case. We thus explored an innovative and original calculation of CFR concurrently based on the date of the first confirmed case as well as on a daily basis. For the first time, we showed that using meta-analyses, according to calendar date and days since the outbreak of the first confirmed case were different. We propose that CFR according to days since the outbreak of the first confirmed case might be a better predictor of the current CFR of COVID-19 and its kinetics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot an intervention studyFunding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yonsei University Medical Center, South Korea, provided an exemption because the study does not involve human or animal subjects or materials.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on the WHO and European Centre for Disease Prevention and Control (ECDC) https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases